Do atypical antipsychotics cause weight gain in nursing home dementia residents?

Consultant Pharmacist

Volumn 19, Issue 9, 2004, Pages 809-812

  Gurevitz, Samuel L ^a,b   Costakis, Terry ^a   Leiter, John ^a  

^a Care Pharmaceutical Services Inc   (United States)

^b INDIANA UNIVERSITY NORTHWEST   (United States)

Author keywords

Alzheimer's disease; Atypical antipsychotics; Dementia; Elderly; Olanzapine; Quetiapine; Risperidone; Weight gain

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGED; AGITATION; ALZHEIMER DISEASE; CONTROLLED STUDY; DEMENTIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NURSING HOME; PSYCHOSIS; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 4644311802     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2004.809     Document Type: Review

References (16)

1. Katz IR, Jeste DV, Mintzer JE et al. Comparisons of risperidone and placebo for psychosis and behavior disturbances associated with dementia: a randomized, double-blind trial. J Clin Psychiatry 1999;60:107-15.
2. DeDeyn PP, Rabheru K, Rasmussen A et al. A randomized trial of risperidone, placebo, and haloperidol for behavior symptoms of dementia. Neurology 1999;53:946-55.
3. Street JS, Clark WS, Gannon KS et al. Olanzapine treatment of psychotic and behavioral in patients with Alzheimer's disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 2000;57:968-76.
4. Brodaty H, Ames D, Snowden J et al. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J. Clin Psychiatry 2003;64:134-43.
5. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and treatment implications. CNS Drugs 2001;15:537-51.
6. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry 2001;62(suppl 23):s5-s12.
7. Wirshing DA, Wirshing WC, Kryar L et al. Novel antipsychotic: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-63.
8. Wetterling T, MuBigbrodt HE. Weight Gaingain: side effect of atypical neuroleptics? J Clin Psychopharmacol 1999;19:316-21.
9. Beasley CM Jr, Tollefson GD, Tran PV. Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 1997;58 (Suppl 10):s7-s12.
10. Borison RL, Arvanitis LA, Miller BG. ICI 204.636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. The U.S. Seroquel Study Group. J Clin Psychopharmacol 1996;16:158-69.
11. Must A, Spradano J, Coakley EH et al. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9.
12. Sandman PO, Adolfsson R, Nygren C et al. Nutritional status and dietary intake in institutionalized patients with Alzheimer's disease and multiinfarct dementia. J Am Geriatr Soc 1987;35:31-8.
13. Reynolds M, Fredman L, Langenberg P et al. Weight, weight change, and mortality in a random sample of older community-dwelling women. J Am Geriatr Soc 1999;47:1409-14.
14. Marion KI, Soc HC Jr, Krupp JR. Involuntary weight loss: diagnostic and prognostic significance. Ann Intern Med 1981;95:568-74.
15. Goldberg RJ. Weight variance associated with atypical neuroleptics in nursing home dementia patients. J Am Med Dir Assoc 2001;2:26-8.
16. Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry 2002;63:117-9.